This is a ready-to-use validation protocol for a relative-potency bioassay, the assay that links your product to its mechanism of action. It covers the reference standard, the dose-response model, parallelism by an equivalence test, system suitability, and the ICH Q2(R2) validation characteristics. Replace every <<FILL: ...>> placeholder and route it through document control. A filled specimen follows. This is general guidance to adapt and verify, not legal or regulatory advice.
Approval page
| Field | Entry |
|---|---|
| Document title | Relative Potency Bioassay Validation, <<FILL: product / assay>> |
| Document number | <<FILL: PROT-ID, e.g. VAL-POT-001>> |
| Version / effective date | <<FILL>> |
| Product / stage | <<FILL: product, phase or commercial>> |
| Method reference | <<FILL: method ID, version>> |
| Supersedes | <<FILL: prior version or "New">> |
| Approval | Name | Signature | Date |
|---|---|---|---|
| Author (Analytical / Bioassay) | <<FILL>> | ||
| Statistics | <<FILL>> | ||
| QC | <<FILL>> | ||
| Quality Assurance | <<FILL>> |
1. Objective
Demonstrate that the relative-potency bioassay for <<FILL: product>> measures the relevant biological activity tied to mechanism of action, reports a valid relative potency against a qualified reference standard, and meets the ICH Q2(R2) validation characteristics across its intended range, so the result is fit for lot release and for supporting future comparability.
2. Scope
Covers validation of the <<FILL: cell-based / reporter-gene / binding-with-functional-link>> relative-potency assay. It does not cover routine testing (governed by the method SOP) nor reference-standard qualification beyond the bridging plan referenced in section 4.
3. Mechanism-of-action link
State the biological activity the assay measures and why it reflects the product’s mechanism of action. A binding or quantity surrogate is acceptable only if its equivalence to the functional activity is demonstrated; otherwise it is a characterization assay, not a potency assay.
| Item | Detail |
|---|---|
| MOA (summary) | <<FILL>> |
| Activity measured | <<FILL: e.g. target-cell killing, cytokine release, reporter signal>> |
| Link to MOA | <<FILL: evidence the readout reflects the clinical mechanism>> |
4. Reference standard and bridging
| Item | Detail |
|---|---|
| Reference standard | <<FILL: primary and working standard, two-tier where appropriate>> |
| Qualification | <<FILL: how qualified>> |
| Bridging plan | <<FILL: how each replacement is bridged with documented equivalence>> |
| Assigned potency | <<FILL: reference defined as 100%>> |
Treat the reference standard as a product: two-tier it, qualify it, and bridge every replacement with documented equivalence. Reference drift silently corrupts every relative-potency result.
5. Assay format and model
| Item | Detail |
|---|---|
| Format | Relative potency vs reference on the same plate |
| Dose-response model | <<FILL: 4-parameter logistic (4PL) or parallel-line>> |
| Reportable value | <<FILL: relative potency %, from n plates/independent assays>> |
| Replication strategy | <<FILL: plates, wells, independent runs averaged>> |
6. System suitability (gates every run)
A run that fails system suitability is invalid, not out of specification; you do not report a potency number from an invalid run.
| Parameter | Criterion |
|---|---|
| Curve fit (R squared) | <<FILL: e.g. NLT 0.98>> |
| Parallelism | Equivalence test on slope/asymptote ratios within <<FILL: pre-set bounds>> |
| Reference EC50 | Within <<FILL: historical range>> |
| Plate / negative controls | <<FILL: within ranges>> |
Use an equivalence test for parallelism, not a difference test. A difference test perversely rewards an imprecise assay by failing to detect non-parallelism; the equivalence approach sets bounds the curves must fall within.
7. Validation characteristics (ICH Q2(R2))
| Characteristic | Design | Acceptance criterion |
|---|---|---|
| Specificity | <<FILL: stressed/degraded vs intact; matrix>> | Detects loss of activity; no interference |
| Accuracy (relative) | <<FILL: known relative potencies, e.g. 50, 70, 100, 140, 200%>> | Mean recovery within <<FILL: %>> |
| Precision: repeatability | <<FILL: replicates, one analyst/day>> | <<FILL: %GCV limit>> |
| Precision: intermediate | <<FILL: analysts x days x instruments>> | <<FILL: %GCV limit>> |
| Linearity (dilutional) | <<FILL: relative potency across dilution series>> | Slope and R squared within <<FILL>> |
| Range | <<FILL: e.g. 50-150% relative potency>> | Accuracy, precision, linearity all met across range |
| Stability-indicating | <<FILL: forced-degraded material>> | Potency decreases with degradation |
For bioassays, relative accuracy and the dilutional linearity of relative potency are central. Report variability as geometric CV where the data are log-normal.
8. Acceptance criteria (overall)
- The assay reads on a relevant biological activity tied to MOA (section 3).
- System suitability, including equivalence-test parallelism, gates every run.
- Accuracy, precision (repeatability and intermediate), specificity, linearity, and range meet their criteria across the intended range.
- The assay is stability-indicating.
- A qualified reference standard exists with a bridging plan.
- The release specification (for example
<<FILL: 50-150% relative potency>>) is justified on clinical and manufacturing experience.
9. Deviation handling, summary, approvals
Record any execution deviation, assess impact, resolve, and re-test as needed. Summarize results versus acceptance, state the validated status and the release specification, and obtain approvals.
Filled specimen (one run, system suitability and reportable)
| Parameter | Reference | Sample | Suitability |
|---|---|---|---|
| Upper asymptote | 2.10 | 2.08 | Within 0.20: pass |
| Lower asymptote | 0.05 | 0.06 | Within range: pass |
| Slope (Hill) | 1.05 | 1.02 | Parallelism equivalence: pass |
| EC50 | 12.4 ng/mL | 10.1 ng/mL | Reference within historical range: pass |
| Curve fit R squared | 0.998 | 0.997 | NLT 0.98: pass |
| Relative potency | 100% (defined) | 123% | Within 50-150% spec: reportable |
Reading: the sample is 123% as potent as the reference. Because the curves pass the parallelism equivalence test and system suitability holds, 123% is a valid reportable value inside the 50-150% release specification. Had the parallelism equivalence test failed, the run would be invalid and repeated or investigated; you do not report a potency number from non-parallel curves.
Common inspection findings this protocol prevents
- A binding or quantity measure used as the sole potency assay when the mechanism involves downstream function.
- Parallelism judged by a difference test that an imprecise assay passes by default.
- Reference standard with no two-tier structure or bridging, so drift goes uncontrolled.
- Intermediate precision never quantified, so assay variability is unknown at release.
How to adapt
- Set your document number and method reference.
- Fill the system-suitability and validation-characteristic criteria from your assay’s development data; do not ship the example numbers.
- For an autologous CGT product that expires before a cell-based assay reads out, pair this with a documented potency assurance strategy (fast qualified release measures correlated with function); see the related article.
- Justify the release specification on clinical and manufacturing experience, and tighten it over the lifecycle.